## RVTY: Revvity, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.1% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.0% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($89.81)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Subscribe to intelligence: R&D’s move towards MaaS**
- Source: R&D World | 20251216T194716 | Bullish | Relevance: 100%
- Revvity has launched Signals Xynthetica, a new Model-as-a-Service (MaaS) platform designed to democratize predictive modeling in R&D. This allows labs to access pre-trained, high-fidelity models, integrate AI tools into experimental workflows, and enhance security by keeping data in-house. The MaaS market, including offerings from AWS and Google, reached $17 billion in 2024 and is projected to grow significantly to $491.5 billion by 2035.

**2. Revvity Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials Discovery**
- Source: PharmiWeb.com | 20251216T160813 | Bullish | Relevance: 100%
- Revvity, Inc. announced the forthcoming introduction of its Signals Xynthetica™ Models-as-a-Service (MaaS) AI offering, designed to augment molecular and materials design. This platform integrates in-silico generation, predictive modeling, and experimental validation in a single environment, aiming to accelerate scientific innovation by connecting AI predictions with real wet-lab outcomes. The offering addresses the gap between powerful AI models and their real-world impact by embedding models directly into scientific workflows.

**3. Revvity (NYSE: RVTY) unveils Signals Xynthetica AI MaaS for discovery workflows**
- Source: Stock Titan | 20251216T130254 | Bullish | Relevance: 100%
- Revvity, Inc. (NYSE: RVTY) has introduced its new Signals Xynthetica™ Models-as-a-Service (MaaS) AI offering within the Revvity Signals platform. This AI-augmented design platform aims to integrate in-silico generation, predictive modeling, and experimental validation to accelerate molecular and materials discovery. The platform addresses the gap between powerful AI algorithms and their real-world impact by seamlessly connecting AI predictions with experimental data in scientific workflows.

**4. Revvity Introduces New AI Service for Molecular, Materials Design**
- Source: 富途牛牛 | 20251217T011032 | Somewhat-Bullish | Relevance: 100%
- Revvity has launched a new AI service designed for molecular and materials design. This announcement was made by MT Newswires. The article also briefly mentioned Unity Software's Q4 earnings, reporting a revenue increase of 35% year-over-year to $609 million and a loss of 66 cents per share.

**5. Revvity to launch AI models-as-a-service for scientific discovery**
- Source: Investing.com Nigeria | 20251216T190851 | Somewhat-Bullish | Relevance: 100%
- Revvity, Inc. is introducing Signals Xynthetica, an AI Models-as-a-Service offering to enhance molecular and materials design for scientific industries. This platform integrates in-silico generation, predictive modeling, and experimental validation, aiming to bridge the gap between AI algorithms and practical scientific workflows. The company, with a market cap of $11.2 billion, expects early access programs to begin in the first half of 2026.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Barclays | $115 | $105 | +10% |
| 2025-12-15 | Wells Fargo | $107 | $102 | +5% |
| 2025-12-09 | Goldman Sachs | $105 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Barclays | main | Overweight |
| 2025-12-15 | Wells Fargo | main | Equal-Weight |
| 2025-12-09 | Goldman Sachs | init | Neutral |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 72.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- T. Rowe Price Invest: 19.9% (-0.6%)
- Vanguard Group Inc: 11.9% (-4.0%)
- Blackrock Inc.: 8.2% (+4.4%)
- Edgepoint Investment: 7.6% (+26.3%)
- Price (T.Rowe) Assoc: 7.2% (+2.4%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.0% 5d) with bearish MACD, trend may be turning.
2. Elevated short interest (9.1%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.66 indicates undervaluation relative to growth. Forward P/E 18.1x stretched relative to 8% growth. Analyst sentiment positive (2 raises, avg +7%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.2B |
| Beta | 1.06 |
| 52W Range | $81.36 - $128.29 |
| Short Interest | 9.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.66 |
| Forward P/E | 18.1 |
| Current P/E | 19.6 |
| YoY Growth | 7.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -0.1% to -2.1% (-2.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.1pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.01x) but short-term weakness (below SMA20). MACD histogram bearish (-0.96), momentum weakening. RSI neutral at 45. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.10% (CS: 17) | Weak |
| RSI_14 | 44.7 | Neutral |
| MACD Histogram | -0.96 | Bearish |
| vs SMA20 | 0.956x | Below |
| vs SMA50 | 0.999x | Below |
| vs SMA200 | 1.012x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $96.23
- **Stop Loss:** $89.81 (6.7% risk)
- **Target:** $102.65 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 147
- **Position Value:** $14,145.81
- **Portfolio %:** 14.15%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-01-26 (Est: $1.55)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.14 | $1.18 | +3.6% |
| 2025Q2 | $1.14 | $1.18 | +3.4% |
| 2025Q1 | $0.95 | $1.01 | +6.4% |
| 2024Q4 | $1.38 | $1.42 | +3.1% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*